Pfizer advances development of drugs to treat obesity - candidate drugs to mid-term testing in the second half
July 11, 2024 20:34 JST
US Pharmaceutical Pfizer is proceeding with the development of weight loss drugs in an attempt to enter the multi-billion dollar obesity treatment drug market.
According to the company's announcement on the 11th, the once-a-day obesity treatment drug candidate “danugripron” is scheduled to proceed with mid-term testing in the second half of this year.
The oral medication danugriprone was developed as a treatment to replace injectable obesity treatments handled by Novo Nordisk and Eli Lilly. Pfizer predicts that oral medications will eventually occupy about one-third of the obesity treatment market.
US Pharmaceutical Pfizer is proceeding with the development of weight loss drugs in an attempt to enter the multi-billion dollar obesity treatment drug market.
According to the company's announcement on the 11th, the once-a-day obesity treatment drug candidate “danugripron” is scheduled to proceed with mid-term testing in the second half of this year.
The oral medication danugriprone was developed as a treatment to replace injectable obesity treatments handled by Novo Nordisk and Eli Lilly. Pfizer predicts that oral medications will eventually occupy about one-third of the obesity treatment market.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
